Illumina, Inc. (NASDAQ: ILMN) today introduced three early-access capabilities on its BioInsight Platform that help ...

Illumina, Inc. introduced three early-access capabilities on its BioInsight Platform that help researchers move faster from sequencing data to discovery. BioInsight Platform Workflow Orchestrator ...

Illumina has introduced three early-access software capabilities on its BioInsight Platform designed to automate informatics ...

Newly ASX-listed Identifai Genetics plans to launch its AI enabled Windrose pre-natal genetic testing platform in the US within months. ... Read More The post Dr Boreham’s Crucible: Identifai brings a ...

"Variant effect prediction tools, such as SpliceAI2, are among the key areas of focus for the BioInsight AI Lab," said Rami Mehio, senior vice president and general manager of BioInsight at Illumina. ...

This video analyzes Illumina's effort to build an AI-driven data moat through its Billion Cell Atlas and the impact this ...

Pacific Biosciences of California's business model struggles to gain traction versus larger, profitable competitors like ...

Illumina, Inc. introduced SpliceAI2, a new genomic AI model designed to address one of the central challenges in genomics: understanding the functional consequences of genetic variation. SpliceAI2 ...

Immunotherapy with checkpoint inhibitors has revolutionized cancer therapy and enabled considerable therapeutic advances for ...

From whole-genome sequencing to magnetic resonance imaging (MRI) and artificial intelligence (AI)-guided diagnostics, these ...

Have you ever come across the term "NGS" in articles about cancer gene panel testing or whole-genome analysis?NGS is a technology that reads DNA base sequences in large quantities.While conventional ...

Building on the momentum from the first half of the year, dealmaking in the life sciences space remained robust in the third quarter of 2026.